Your browser is no longer supported. Please, upgrade your browser.
Settings
OMCL Omnicell, Inc. daily Stock Chart
OMCL [NASD]
Omnicell, Inc.
Index- P/E65.95 EPS (ttm)1.13 Insider Own2.00% Shs Outstand42.66M Perf Week6.41%
Market Cap3.16B Forward P/E25.47 EPS next Y2.93 Insider Trans-3.53% Shs Float42.20M Perf Month11.97%
Income49.10M PEG4.40 EPS next Q0.50 Inst Own99.67% Short Float5.34% Perf Quarter8.85%
Sales906.40M P/S3.49 EPS this Y53.50% Inst Trans4.45% Short Ratio5.81 Perf Half Y20.05%
Book/sh20.80 P/B3.59 EPS next Y30.38% ROA4.00% Target Price81.75 Perf Year3.38%
Cash/sh3.15 P/C23.69 EPS next 5Y15.00% ROE5.70% 52W Range54.24 - 94.85 Perf YTD-8.64%
Dividend- P/FCF21.93 EPS past 5Y11.40% ROI7.30% 52W High-21.29% Beta0.81
Dividend %- Quick Ratio1.50 Sales past 5Y15.30% Gross Margin47.60% 52W Low37.65% ATR2.41
Employees2700 Current Ratio2.00 Sales Q/Q-8.20% Oper. Margin5.70% RSI (14)59.31 Volatility2.97% 3.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-127.10% Profit Margin5.40% Rel Volume1.10 Prev Close72.50
ShortableYes LT Debt/Eq0.00 EarningsJul 28 AMC Payout0.00% Avg Volume387.89K Price74.66
Recom2.20 SMA203.44% SMA506.56% SMA2002.32% Volume428,403 Change2.98%
Jul-07-20Initiated Stephens Overweight $90
Feb-07-20Reiterated Dougherty & Company Buy $92 → $100
Nov-21-19Reiterated Dougherty & Company Buy $90 → $92
Jul-26-19Upgrade Craig Hallum Hold → Buy $85
Mar-07-19Reiterated Dougherty & Company Buy $78 → $90
Jun-29-18Resumed The Benchmark Company Buy $63
Sep-05-17Reiterated The Benchmark Company Buy $55 → $67
Jul-28-17Reiterated Dougherty & Company Buy $45 → $49
Apr-21-17Downgrade Piper Jaffray Overweight → Neutral
Jan-19-17Initiated Dougherty & Company Buy $44
Dec-06-16Reiterated The Benchmark Company Buy $39 → $55
Jul-07-16Reiterated FBR Capital Outperform $35 → $40
Mar-21-16Reiterated Topeka Capital Markets Buy $38 → $37
Jan-07-16Initiated The Benchmark Company Buy $33
Nov-16-15Reiterated Topeka Capital Markets Buy $40 → $38
Oct-30-15Reiterated FBR Capital Outperform $40 → $35
Sep-28-15Upgrade Sidoti Neutral → Buy
Jul-31-15Reiterated Topeka Capital Markets Buy $39 → $40
Jul-31-15Reiterated Oppenheimer Outperform $44 → $42
Jun-18-15Initiated Oppenheimer Outperform $44
Sep-29-20 04:53PM  
Sep-23-20 11:24AM  
06:45AM  
Sep-22-20 07:00AM  
Sep-08-20 01:13PM  
Sep-01-20 04:15PM  
Aug-27-20 11:31AM  
Aug-18-20 10:51AM  
Aug-17-20 09:10AM  
08:00AM  
Aug-12-20 10:02AM  
08:00AM  
Aug-11-20 12:04PM  
11:57AM  
Jul-29-20 09:54AM  
Jul-28-20 10:01PM  
05:33PM  
04:01PM  
Jul-21-20 04:01PM  
Jul-20-20 08:00AM  
Jul-16-20 12:32PM  
Jun-25-20 08:13AM  
Jun-24-20 10:38AM  
Jun-11-20 11:40AM  
Jun-05-20 10:02AM  
May-08-20 10:08AM  
03:01AM  
May-07-20 04:01PM  
May-01-20 04:05PM  
Apr-30-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 12:31PM  
Apr-01-20 11:40AM  
Mar-27-20 10:47AM  
Mar-16-20 05:57PM  
11:40AM  
Mar-12-20 09:17AM  
Mar-07-20 11:31AM  
Mar-05-20 08:30AM  
Feb-19-20 08:06AM  
Feb-13-20 08:49AM  
Feb-12-20 11:40AM  
Feb-10-20 08:00AM  
Feb-07-20 09:31AM  
Feb-06-20 05:25PM  
04:01PM  
02:30PM  
Feb-03-20 08:01AM  
Jan-30-20 04:05PM  
12:31PM  
Jan-28-20 10:49AM  
08:00AM  
Jan-26-20 11:00PM  
Jan-21-20 09:21AM  
08:17AM  
08:00AM  
Jan-20-20 07:34AM  
Jan-16-20 07:01AM  
Jan-15-20 06:48AM  
Jan-14-20 08:36AM  
Jan-13-20 08:39AM  
Jan-09-20 05:52AM  
Jan-07-20 11:12AM  
10:54AM  
10:08AM  
09:35AM  
09:09AM  
Jan-06-20 04:24PM  
07:53AM  
Jan-03-20 10:48AM  
08:36AM  
Dec-31-19 10:53AM  
10:45AM  
Dec-30-19 11:47AM  
09:31AM  
08:44AM  
Dec-27-19 10:16AM  
08:47AM  
Dec-18-19 08:21AM  
Dec-17-19 08:22AM  
05:00AM  
Dec-14-19 07:47PM  
Dec-12-19 07:22AM  
Dec-10-19 10:04AM  
09:00AM  
08:48AM  
06:38AM  
Dec-09-19 08:59AM  
08:01AM  
08:01AM  
Dec-06-19 07:04AM  
Dec-05-19 08:01AM  
Nov-25-19 09:30AM  
09:10AM  
Nov-22-19 07:56AM  
Nov-19-19 04:01PM  
Nov-05-19 09:30AM  
Oct-31-19 02:20PM  
Oct-27-19 03:01AM  
Oct-25-19 11:42AM  
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIPPS RANDALL AChairman, President and CEOSep 16Sale75.6413,7431,039,501240,548Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOSep 15Sale75.011,400105,009254,291Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOJul 29Sale75.153,718279,398148,398Jul 30 12:42 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerJun 16Sale67.702,125143,86931,260Jun 17 05:09 PM
LIPPS RANDALL AChairman, President and CEOMay 14Option Exercise60.395,500332,145162,352May 14 06:42 PM
LIPPS RANDALL AChairman, President and CEOMay 13Option Exercise59.362,450145,432156,852May 14 06:42 PM
LIPPS RANDALL AChairman, President and CEOApr 03Sale66.115,000330,566259,409Apr 03 04:58 PM
LIPPS RANDALL AChairman, President and CEOApr 02Sale62.935,000314,631264,409Apr 03 12:13 PM
Bauer Joanne BDirectorFeb 19Sale88.422,919258,11215,916Feb 19 06:29 PM
Kuipers Peter J.Executive V P& CFOFeb 14Option Exercise0.0011,267070,285Feb 18 02:38 PM
Kuipers Peter J.Executive V P& CFOFeb 14Sale89.7911,2671,011,63759,018Feb 18 02:38 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerFeb 10Option Exercise0.002,833026,474Feb 11 12:16 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerFeb 10Sale86.372,833244,69823,641Feb 11 12:16 PM
LIPPS RANDALL AChairman, President and CEOJan 07Option Exercise0.0024,0000140,466Jan 08 04:28 PM
LIPPS RANDALL AChairman, President and CEOJan 07Sale81.435,000407,143284,409Jan 08 04:28 PM
LIPPS RANDALL AChairman, President and CEOJan 07Sale81.4124,0001,953,852116,466Jan 08 04:28 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerDec 16Sale80.591,356109,28123,641Dec 16 04:47 PM
JOHNSTON DAN SEVP & Chief Legal & AdminNov 29Option Exercise0.006,250034,076Dec 02 02:31 PM
JOHNSTON DAN SEVP & Chief Legal & AdminNov 29Sale80.389,086730,29924,990Dec 02 02:31 PM
LIPPS RANDALL AChairman, President and CEONov 21Option Exercise0.0020,9020149,311Nov 22 11:23 AM
LIPPS RANDALL AChairman, President and CEONov 21Sale78.7520,9021,646,018128,409Nov 22 11:23 AM
Seidelmann Scott PeterEVP, Chief Commercial OfficerNov 15Option Exercise0.002,833029,166Nov 15 05:50 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerNov 15Sale75.002,833212,47526,333Nov 15 05:50 PM
LIPPS RANDALL AChairman, President and CEOOct 25Option Exercise0.001,1720129,659Oct 28 04:33 PM
LIPPS RANDALL AChairman, President and CEOOct 25Sale78.001,17291,416128,487Oct 28 04:33 PM
LIPPS RANDALL AChairman, President and CEOOct 21Option Exercise0.0025,9260154,413Oct 21 07:01 PM
LIPPS RANDALL AChairman, President and CEOOct 21Sale78.0325,9262,022,990128,487Oct 21 07:01 PM
LIPPS RANDALL AChairman, President and CEOOct 18Sale76.045,000380,202289,409Oct 21 07:01 PM
LIPPS RANDALL AChairman, President and CEOOct 18Sale76.045,000380,202289,409Oct 18 06:01 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerOct 11Option Exercise0.001,534027,867Oct 11 06:02 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerOct 11Sale75.261,534115,45426,333Oct 11 06:02 PM